Pharmacotherapy of osteoporosis:: Evidence-based clinical practice

Since the foundation of the DVO ("Dachverbind Osteologie") in 1999, it has been the Continuous ambition to implement evidence-based medicine in the clinical course for the effective diagnosis and treatment of osteoporosis. This aim was addressed by the implementation of general guidelines (DVO) in 2003. These guidelines (DVO) offer strategies for diagnosis and treatment of osteoporosis in postmenopausal women, osteoporosis in elderly women and glucocorticoid-induced osteoporosis. Evidence-bised treatment of osteoporosis reconiniends the supplementation with calcium and vitamin D, considering intiresorptive therapy antifracture efficacy is proven for the bisphosphonates alendronate, ibandronate and risedronate on the one hand and the SEKMraloxifen oil the other hand. On the basis of valid data from randonlized, placebo-controlled clinical trials, new therapy regirnen hke rhPTHl-34 (teriparatide) or strontium ranelate fulfill the reconui-icndation criteria for the guidelines (DVO). Effective treatment of glucocorticoid-induced osteoporosis includes Supplemental calciurn and vitarnin D and antiresorptive agents like the bisphosphonates alendronate, risedronate and etidronate according to the guidelines (DVO).